Stay ConnectedPodcast interviews with genius-level (top .1%) practitioners, scientists, researchers, clinicians and professionals in Cancer, 3D Bio Printing, CRISPR-CAS9, Ketogenic Diets, the Microbiome, Extracellular Vesicles, and more.
Subscribe today for the latest medical, health and bioscience insights from geniuses in their field(s).
Copyright: © Richard Jacobs
Dr. Abdul Kadir Slocum is a co-founder of Chemothermia, an oncology center in Turkey that combines conventional cancer treatments with "out-of-the-box" therapies to improve cancer treatment outcomes. Dr. Slocum began the clinic in 2010 in Turkey with two partners, Professor Bulent Berkarda, M.D., and Professor Mehmet Salih İyikesici, M.D. to treat cancer patients from around the world.
Click on play to learn:
Dr. Slocum has been working with Dr. İyikesici and Dr. Berkarda on the development and application of conventional and unconventional cancer treatments such as oxygen therapy for cancer to support and balance the system. These supportive treatments give the patient more time to fight the disease.
Therapies include metabolically supported chemotherapy, hyperthermia (local and whole body) therapy, hyperbaric oxygen therapy, and the ketogenic diet that all work synergistically with the standard conventional cancer treatments. Integrating the genetic and metabolic approaches with supportive strategies can maximise the efficacy of conventional treatments and reduce their side effects.
Chemothermia claims to have one of the highest success rates in the world with their unique approach on cancer treatment. The clinic publishes their results in leading peer reviewed journals. Patients with stage 3 and stage 4 cancers can be treated at the clinic. Doctors develop personalized protocols for each patient treated at the clinic with promising results.
To learn more visit: chemothermia.com Episode also available on Apple Podcasts: apple.co/30PvU9C
"This is one of the biggest stories ever," says T. Colin Campbell.
What story is he talking about?
The one that offers clear evidence of a safe, natural, and effective way to reverse cancer, diabetes, heart disease, and more.
Tune in to discover:
T. Colin Campbell grew up on a farm, which meant growing up on dairy and animal meat. His doctoral dissertation was on the importance of animal protein consumption, and he even led a program in the Philippines aimed at helping malnourished children by providing them with quality animal proteins. His belief was firm, and in line with the rest of the nutritional science community: malnourishment results from inadequate amounts of quality protein from animal sources.
But in reality, he encountered evidence which completely challenged this position: the Filipino children who were consuming animal protein like those in the Western world were at a higher risk of developing liver cancer. Animal studies showed the same thing: animals who consumed animal protein were more susceptible to the rapid growth of liver cancer.
Campbell was faced with a dilemma: would he move forward with all the work he'd already promoted, or back up and carefully re-examine the evidence? He chose the latter, and received plenty of NIH funding to study whether animal protein really does cause cancer.
The answer? An emphatic "Yes," says Campbell. He has since published extensively on the topic and even served on government policy boards.
"The further I got into this story and learned so much about it—not just about animal protein itself but also about the entire medical system and the way we actually tell the public the information we tell them—the more I realized there's a serious problem here," says Campbell.
Heart disease, diabetes, and cancer are just a few of the diseases that can be treated and altogether reversed through a whole foods, plant-based diet.
Interested in learning more?
Press play, and visit https://nutritionstudies.org/. Episode also available on Apple Podcasts: apple.co/30PvU9C
How can early detection and regular monitoring of breast health play a significant role in the severity of breast cancer? The earlier cancer can be detected, a significant possibility emerges that an early understanding can benefit the patient when treatment begins. Listen in to learn:
Professor of Medicine at Harvard Medical School and member of the Dana-Farber Cancer Institute, Kornelia Polyak, shares her research on the monitoring and preventing breast cancer.
Through understanding why and when an individual gets breast cancer, better treatment techniques may become available, and prevention methods can be uncovered. In addition, through a deeper understanding of cause and early behavior, the next stages of treatment and prevention research can progress.
The location of tumors and the environment within the body can play a significant part in determining the heterogeneity of cancer. This level of heterogeneity is one of the defining characteristics of how to treat and prevent tumors.
For more information, visit polyaklab.dfci.harvard.edu. Episode also available on Apple Podcasts: apple.co/30PvU9C
Finally, you can take a deep breath in and relax…knowing you've also taken the lowest efficacious dose of your medicine, with less worry over adverse events. And it's all thanks to a company called TFF Pharmaceuticals.
Press play to learn:
Glenn Mattes has worked in the pharmaceutical industry for over forty years now, and for the past four years, has served as CEO of TFF Pharmaceuticals, a Thin Film Freezing technology platform that can improve the properties of drug formulation, delivery, and administration while maintaining efficacy and avoiding many adverse events associated with other drug therapies.
The Thin Film Freezing technology uses flash freezing to capture pharmaceutical drugs in a highly active state and convert them into highly concentrated powders. These powders can then be put into a capsule and inhaler device, allowing for administration directly into the lungs. Since the lung is an ideal organ for drug metabolism and distribution throughout the body, lower doses of the drug can be used to achieve the same or better efficacy with lower incidence of adverse events.
Other substances being formulated at TFF Pharmaceuticals can be inhaled through the nose, and in the works is a formulation that can be applied to the eyes or skin.
Mattes explains the science behind this technique, including the details of how and why it works, and the specific ways in which it can be applied.
Learn more at https://tffpharma.com/. Episode also available on Apple Podcast: http://apple.co/30PvU9C
"When psychiatry became wedded with the drug companies, it became very little more than a sales department of the pharmaceutical industry," says Dr. Peter Breggin.
He explains the pre-wedding state, post-wedding state, the future of psychiatry, and how it's all related to the current virus situation.
Tune in to discover:
Dr. Breggin is a psychiatrist and author of over 20 books, with one of his most recent publications addressing the current virus situation and the influence of global predators.
He's been involved with reform work his whole life, starting with giant volunteer projects in state mental hospitals over 60 years ago, to taking on almost all major lobotomy programs in the US since then, and to this very day, trying to tackle electroshock therapy, and what he calls "chemical lobotomies" through psychiatric drugs.
Dr. Breggin is the first psychiatrist to take various issues to the courtroom, and has been in trial over 100 times. Along the way, he's been attacked and slandered by scientists, clinicians, fellow psychiatrists, and the medical-scientific establishment at large, but nonetheless remains firm in his stance against what he perceives to be unethical and even violent practices aimed at controlling humanity.
In today's show, he reveals these practices in detail and explains how they are intimately tied to the current virus situation.
Tune in to hear the full conversation. Visit www.wearetheprey.com to check out his latest book and learn more. Episode also available on Apple Podcasts: apple.co/30PvU9C
"All malignant diseases are derived from a normal cell in the body," says Dr. Owen O'Connor, MD, PhD. But how different are the malignant cells from the normal ones, and how hard is it to differentiate one from the other?
This question is at the heart of the 'therapeutic window' problem in cancer treatment. But with new research in full swing, a solution may be within reach.
Press play to learn:
Dr. O'Connor is an international authority on lymphoma and drug development with over 25 years of experience in academic medicine. He is also Chief Scientific Officer at TG Therapeutics, a biotechnology company that focuses on targeting diseases related to underlying B cell dysfunction, like non-Hodgkin's lymphoma and some autoimmune diseases.
B cells are a type of white blood cell that produce antibodies designed to rid the body of pathogens. In lymphoma and some autoimmune diseases, however, these normal B cells begin wildly misbehaving or proliferating rapidly. In the case of malignant disease, the goal is to inhibit the proliferation of and kill these B cells; in the case of autoimmune disease, the goal is to suppress their activity and interactions with other cells in the body.
How is this accomplished? And what's wrong with most modern chemotherapies?
Answering these questions leads Dr. O'Connor to discuss the meaning of the therapeutic window and two drugs that have been acquired and studied extensively by the team at TG Therapeutics. One of these drugs is an immunotherapy, and the other is a precision targeted therapy. The idea is that working together, these drugs could provide an effective treatment without the serious downsides of chemotherapies.
Visit https://www.tgtherapeutics.com/ to learn more. Episode also available on Apple Podcasts: apple.co/30PvU9C
Kiana Aran, Ph.D. is an associate professor and director of the Aran Lab at Keck Institute and is also the Chief Scientific Officer at Cardea Bio. She is an electrical engineer with a driving interest in biology that has led her to combining these two seemingly unconnected fields. Her research has led to the discovery that amplification is not required for targeted DNA and gene detection.
Click on play to learn:
Dr. Aran is interested in the integration electrical, mechanical, chemical, and bioengineering to develop new device solutions for use in clinical research. She thinks of the CRISPR chip as a microscopic robot that can be used as a genome typing tool, a kind of DNA search engine. This tool provides the ability to search through a complete genome in record time, among other things.
Currently, the sensitivity of the platform is being evaluated and improved to allow for more types of research. Work is currently being conducted to assess the accuracy and efficiency of CRISPR itself. Research continues on combining the power of CRISPR in its search capabilities and the power of biology as a technology to facilitate research and new discoveries.
To learn more visit: aranlab.org and cardeabio.com Episode also available on Apple Podcasts: apple.co/30PvU9C
A cure for cancer? Immunotherapy could be the key.
Tune in to discover:
Samantha Bucktrout is the senior director of research at Parker Institute for Cancer Immunotherapy, where she focuses on bringing curative immunotherapy for patients with cancer.
She begins by explaining the basics of immunotherapy, noting that all throughout each and every day, our immune systems are at work detecting and eliminating pre-cancerous cells in the body.
For patients who have developed metastasis and where the standard of care has failed, immunotherapy might provide promise. Research in immunology has led to an understanding of the ways in which cancer co-opts the body's natural ability to regulate the immune system, and thereby actively blocks it from doing its job. Equipped with this knowledge, it's possible to block the barriers put up by cancer through the use of antibodies.
Immunotherapy, in some cases, can be considered to 'cure' patients who otherwise have fatal metastatic processes.
Bucktrout discusses how chemotherapy affects the immune response, when it is used as the sole approach to cancer treatment as opposed to in conjunction with chemotherapy, how cancer cells may have evolved to evade the immune response, and much more.
Press play to hear the full conversation and learn more at https://www.parkerici.org/. Episode also available on Apple Podcasts: apple.co/30PvU9C
"If you can't sleep, so what?" asks Annie Miller.
Well, you may or may not agree, but the point she's making is that it's far better to not care about a lack of sleep than to panic about it.
Press play for more of her insights and learn:
Annie Miller is a psychotherapist and the founder of DC Metro Sleep and Psychotherapy, a private practice in Bethesda, Maryland. Her specialties include sleep and insomnia, anxiety, trauma, and chronic pain.
In today's show, she discusses how the current virus situation has been impacting people's anxiety and sleep health, and also explains her approach to helping people through these issues. In the process, she provides several tips on establishing and maintaining good sleep hygiene.
Tune in for all the details and visit https://dcmetrotherapy.com/ to learn more. Episode also available on Apple Podcasts: apple.co/30PvU9C
How can Diabetes treatment be made more accessible and easy to use? By encouraging the availability of products to be all under one roof and finding less invasive treatment methods, patients can find new ease of lifestyle. Listen in to learn:
Ali Dianaty, the vice president of product innovation for the Diabetes Business at Medtronic, shares his work developing products to ease the burden placed on diabetes patients.
In recent history, patients who have Diabetes were limited to very scarce, expensive, and painful treatment techniques. However, by innovating using machine learning, pumps, and similar therapeutic methods, the lifestyle surrounding Diabetes has changed and simplified treatment for many.
With data storage and algorithms working with smartphone apps, devices may even remember meals one has consumed in the past and automatically adjust treatment. This will allow patients to build a database of normal behavior, tailoring treatment specifically to their lifestyle.
To learn more, visit medtronicdiabetes.com/home. Episode also available on Apple Podcasts: apple.co/30PvU9C
Our TOPPODCAST Picks 
